Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Grifols bleeding disorder drug authorized
Alphanate is the first and only dual inactivated and affinity chromatography purified antihemophilic factor/von Willebrand factor complex that is FDA approved for the treatment of von Willebrand disease
Alphanate is the first and only dual inactivated and affinity chromatography purified antihemophilic factor/von Willebrand factor complex that is FDA approved for the treatment of von Willebrand disease
The collaboration was originally signed in 2004 to ensure sufficient production capacity from several facilities, and distribution of Imvamune to various international markets as Bavarian Nordic did not
The vaccine will be developed using DelSite’s proprietary GelSite polymer delivery technology. As part of the agreement, DelSite will provide assistance in the vaccine formulation development. DelSite said
The milestone was achieved with the completion of phase I clinical testing of Hematide in normal healthy volunteers in Japan. “We look forward to continued progress in the
“The acquisition is a further step in Pfizer's strategy to accelerate our business development and licensing activity while ensuring appropriate operational and financial discipline,” said David Shedlarz, vice
The FDA's Division of Bioequivalence has determined the Ranbaxy formulation to be bioequivalent and therapeutically equivalent to Valtrex Caplets, developed by GlaxoSmithKline. Valacyclovir HCl is indicated for the
Under the agreement, Fresenius Medical Care, a company focused on renal therapy, will assist Amgen in disseminating scientific information regarding the treatment of anemia to nephrologists and other
The compound, CS-917, is being developed by Daiichi Sankyo pursuant to a licensing agreement between the two companies. This proof-of-concept study is designed to evaluate safety and tolerability
Solvay Pharmaceuticals will retain the right to market both products in other territories around the world. Solvay's Luvox, also known as fluvoxamine, was introduced in 1983 in Europe
The immunotherapeutic vaccine, AE37, is being developed by Generex' Antigen Express division in the US. The phase II study will enroll patients who have completed standard therapy for